drugset / Trial / NCT04032964

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

NCT04032964

Phase 1 Unknown 2 enrolled Philogen S.p.A.
NaSequentialOpen-labelTreatment

Summary

The study is aimed at evaluating the safety of L19TNF in combination with the most appropriate dose of doxorubicin.

Timeline

Start
2019-09-05
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 75 mg/m2 Intravenous
Subject Onfekafusp alfa Protein / enzyme biologic 13 ug/kg Intravenous

Indications